Today we are revisiting a topic and episode that was originally aired back when Journal Club was part of the a16z podcast. We are covering it again in light of a new research article published in Science, as both this episode and this newer research article are trying to find a way to kill senescent cells.
The article we discuss in this episode, “Senolytic CAR T cells reverse senescence-associated pathologies” by Amor et al, published in Nature, selectively targets senescent cells with engineered T cells.
The new article, “Senolysis by glutaminolysis inhibition ameliorates various age-associated disorders” by Johmura et al, published in Science, kills senescent cells by inhibiting an enzyme essential for their metabolism.
So what are senescent cells, and why is killing them so important? Senescent cells are those in a non-dividing but metabolically active state, and what’s interesting is that they play both protective and pathological roles in the body. When senescent cells accumulate, as often happens during aging, they kick off an inflammatory process that underlies many age-related diseases. Thus the targeted destruction of senescent cells has the potential to treat a wide range of conditions, and possibly to improve longevity. Each of the approaches described in these articles have their pros and cons, and it remains to be seen which will be effective in humans, but together they highlight the interest and importance of senescence-killing, or senolytic, methods for future therapeutics.
Jorge Conde is a General Partner on the Bio + Health team, focused on therapeutics, diagnostics, life sciences tools, and software.
Andy Tran is a Principle at Matrix Capital Management Company.
Lauren Richardson is the Founder and Principal of LR Bio LLC.
Between the growing ability to engineer biology for therapeutics, and the integration of tech into how patients receive care, bio and health are fundamentally changing the world. Join the team at a16z and host Olivia Webb as they discuss these transformations with scientists, builders, and leaders.